Safety and efficacy of topical agents in primary open angle glaucoma- latanoprost versus combination of latanoprost & timolol maleate

---

Original Article

Author Details : Shilpi Agarwal, Sugyani Satapathy, Mukta Prasad*

Volume : 7, Issue : 3, Year : 2021

Article Page : 289-293

https://doi.org/10.18231/j.ijooo.2021.059

Suggest article by email

Get Permission

---

Abstract

Aims: This prospective drug trial was done to compare latanoprost versus combination therapy of latanoprost and timolol maleate.
Methods and Materials: Patient were screened for primary open angle glaucoma and grouped as per pharmacological drugs used and measured IOP baseline before initiation of study. Group I consisting all patients with latanoprost monotherapy and Group II consisting of patients already using either latanoprost or timolol. Further A,B & C was assigned as per IOP baseline.
Results: In group I (Monotherapy), 28 patients were completed the follow up. The mean baseline IOP was 27.4 millimeter of Hg with standard deviation of 2.59. After 12 weeks of study, mean IOP was 19.66 millimeter of Hg with SD of 2.76. Mean IOP difference from baseline was 7.4 millimeter of Hg. So fall of 27.3% in IOP from pre-treatment level. In group II (Combination therapy), 19 patients were completed the follow up. The mean baseline IOP was 27.35 millimeter of Hg with standard deviation of 2.6. After 12 weeks of study mean IOP difference from baseline was 8.1 millimeter of Hg with SD of 2.0 millimeter of Hg i.e. a fall of 29.63% in IOP from pre-treatment level.
Conclusions: Combination therapy fared slightly better that Latanoprost alone in overall pressure reduction.
 
Keywords: Prostaglandins, Glaucoma, Timolol, Beta adrenergic, Dual therapy

How to cite : Agarwal S, Satapathy S, Prasad M, Safety and efficacy of topical agents in primary open angle glaucoma- latanoprost versus combination of latanoprost & timolol maleate. IP Int J Ocul Oncol Oculoplasty 2021;7(3):289-293

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.